Scinawa, Poland Clinical Trials — 10 Studies

Filter these 10 trials by phase, condition, sponsor and more.

Open in Search →

A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 5 2025-11-12 Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)
A study to assess the efficacy and safety of ITI-1284 in the treatment of Psychosis Associated with Alzheimer's Disease Recruiting

2024-513035-25-00 4 2025-07-11 Psychosis associated with Alzheimer’s Disease
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting

2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment

2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
A study to see how well KarXT works and how well tolerated it is in participants with psychosis associated with Alzheimer’s disease. Ended recruitment

2023-504416-16-00 5 2024-04-11 Psychosis Associated with Alzheimer’s Disease
A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended

2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Ended

2023-506918-45-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended

2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended

2023-504990-19-00 5 2021-04-06 Agitation in Patients With Dementia of the Alzheimer's Type
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 4 2020-09-30 Alzheimer Disease

Showing 1–10 of 10 trials